WuXi AppTec Inc.

WuXi AppTec Inc.
Share

WuXi AppTec Inc.

 •  April 19

Press Releases SHANGHAI and CRANBURY,NJ, April 18, 2018 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, todayannounced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey. The grand opening event was honored by the presence of state and local...

WuXi AppTec Inc.

 •  February 22

STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTec group company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs,...

WuXi AppTec Inc.

 •  November 17, 2017

Press Releases Philadelphia, November 17 2017 – WuXi AppTec (WuXi), a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, announced that its Advanced Therapy Unit based in Philadelphia has been selected as a manufacturing partner for advanced therapies through the California...

WuXi AppTec Inc.

 •  May 15, 2017

Press Releases SHANGHAI, May 15, 2017 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has completed its acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization...

WuXi AppTec Inc.

 •  March 1, 2017

Press Releases Shanghai, Mar.1, 2017—WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, today announced that its Lab Testing Division(LTD)'s Bioanalytical facility in Shanghai once again passed US FDA's bioequivalence (BE) inspection with no 483 observations. The...

WuXi AppTec Inc.

 •  November 25, 2016

A new mouse model developed by scientists at the U.S. Food and Drug Administration may help in exploring the potential activity of Zika virus vaccines and therapeutics. Published November 17 in PLoS Pathogens, is the description of a neonatal mouse model that provides a platform for potentially improving and expediting studies to understand the...

WuXi AppTec Inc.

 •  November 23, 2016

WuXi Biologics, a WuXi AppTec group company and a leading open-access R&D capability and technology platform company dedicated to expediting global biologics development, and Prima Biomed Ltd. (Prima), an ASX (PRR) and Nasdaq (PBMD) listed company developing IMP321, a recombinant soluble LAG-3 protein and other LAG-3 related products for use in...

WuXi AppTec Inc.

 •  April 6, 2016

The U.S. Food and Drug Administration, on December 7, 2016 announced important steps to better support consumer access to hearing aids. The agency issued a guidance document explaining that it does not intend to enforce the requirement that individuals 18 and up receive a medical evaluation or sign a waiver prior to purchasing most hearing aids....